Ameriprise’s Rubius Therapeutics RUBY Stock Holding History
Bought
Maintained
Sold
Other funds holding RUBY
AG
Ameriprise's RUBY Position: Q2 2022 in Review
Ameriprise sold out of Rubius Therapeutics (RUBY) in Q2 2022, closing a stake of 93,139 shares — an estimated $513K sold.
Ameriprise first reported a position in RUBY in Q4 2018 and held it in 14 quarters. The position peaked at $2.11M in Q2 2019. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.
- Ameriprise reported no remaining Rubius Therapeutics position as of Q2 2022 after selling out during the quarter.
- Ameriprise sold 93,139 Rubius Therapeutics shares in Q2 2022, an estimated $513K.
- Ameriprise first reported a position in Rubius Therapeutics in Q4 2018 and held it in 14 quarters.
- Ameriprise's Rubius Therapeutics position peaked at $2.11M in Q2 2019.
- 72 funds tracked by Wall St. Rank held Rubius Therapeutics as of Q2 2022.
Based on Ameriprise's 13F filing for Q2 2022, filed 15 Aug 2022.